Sandy Mahatme is currently Senior Vice President, Chief Financial Officer at Sarepta Therapeutics, and was elected to the Elcelyx Board of Directors in 2016. Prior to joining Sarepta in 2012, Sandy worked at Celgene Corporation, a biopharmaceutical company, where he served in various roles, including Senior Vice President of Corporate Development, Senior Vice President of Finance, Corporate Treasurer and Head of Tax. While at Celgene, Sandy built the treasury and tax functions before establishing the Corporate Development Department, focused on strategic, targeted initiatives including commercial development in emerging markets, acquisitions and licensing and global manufacturing expansion. Prior to working at Celgene, Sandy worked for Pfizer Inc., a pharmaceutical company, for eight and a half years in senior roles in Business Development and Corporate Tax.
Sandy started his career at Ernst & Young LLP where he advised multinational corporations on a broad range of transactions. He holds Master of Laws (LL.M.) degrees from Cornell Law School and NYU School of Law and is a member of the New York State Bar Association. Sandy is also a board member of Flexion Therapeutics, Inc and Aeglea Biotherapeutics.